

# SDZ 220-581

Catalog No: tcsc1475



## Available Sizes

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

174575-17-8

**Formula:**

$C_{16}H_{17}ClNO_5P$

**Pathway:**

Membrane Transporter/Ion Channel;Neuronal Signaling

**Target:**

iGluR;iGluR

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 8.57 mg/mL (23.18 mM; Need ultrasonic and warming)

**Observed Molecular Weight:**

369.74

## Product Description


SDZ 220-581 is a potent, competitive antagonist at the NMDA glutamate receptor subtype(pKi= 7.7).

IC50 Value:

Target: NMDA receptor

in vitro: Wake-promoting doses of LSN2463359 and LSN2814617 attenuated deficits in performance induced by the competitive NMDA receptor antagonist SDZ 220,581 in two tests of operant behaviour: the variable interval 30 s task and the DMTP task [1].

in vivo: Administration of SDZ 220-581 or CGS 19755 was associated with a robust reduction in PPI, whereas L-701,324, 4-Cl-KYN or MLA failed to alter PPI [2]. With the most active agent, SDZ 220-581, full protection against maximal electroshock seizures (MES) was obtained at oral doses of 10 mg/kg in rats and in mice. The compound had a fast onset (onset = 24 hr) of action [3]. Rats were pretreated with clozapine (0 or 5.0 mg/kg) or haloperidol (0 or 0.1 mg/kg), together with SDZ 220-581 (0 or 2.5 mg/kg), and tested. SDZ 220-581 and SDZ EAB-515 decreased PPI without affecting startle magnitude [4].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!